

CURRICULUM VITAE

1. PERSONAL DETAILS:

Full Name: Yaacov Baruch

2. ACADEMIC DEGREES:

1977 M.D., Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.

3. ACADEMIC APPOINTMENTS:

2002- Present Clinical Associate professor, Liver Unit, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.

2005-2006 Associate visiting professor, Department of medicine, Division of Gastroenterology, University of Texas, Houston, USA.

2002 Visiting professor – Winnipeg health science center (Canada).

1996- Clinical senior lecturer, Department of Internal Medicine, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.

1995 Visiting professor at the university of Manitoba (Canada).

1991- Clinical lecturer, Department of Internal Medicine, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.

1986- Clinical instructor, Department of Internal Medicine, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.

4. PROFESSIONAL EXPERIENCE:

1995-present Director, Liver Unit, Rambam Medical Center, Haifa.

2012 Medical advisor to Coeruleus Ltd.

2005-2006 Senior Transplant Hepatologist and Gastroenterologist, Division of Gastroenterology and Nutrition, Herman Memorial Hospital, Houston, Texas.

1986-2000 Deputy head, Department of Medicine B, Rambam Medical Center, Haifa.

1986-1995 Head, follow-up clinic for patients after liver transplant, Rambam Medical Center, Haifa.

1988 - Special training in intravenous liver biopsy, Beaujon Hospital, Clichy, France.

1986-1988 Experience with gastrointestinal endoscopy, including endoscopic retrograde cholangiography.

- 1983-1988 Residency in Gastroenterology, Rambam Medical Center, Haifa.
- 1987 - Two months' clinical experience in long-term treatment of patients after liver transplant, Presbyterian-University Hospital, Pittsburgh, Pennsylvania, U.S.A.
- 1983-1985 Research fellowship, Liver and Gastrointestinal Units, Groote-Schuur Hospital, University of Cape Town, South Africa.
- 1978-1983 Residency in Internal Medicine, Rambam Medical Center, Haifa.
- 1977-1978 Internship, Hadassah Medical Center, Jerusalem.

Qualifying examinations passed

- 1990 - Israel Board of Gastroenterology.
- 1983 - E.C.F.M.G. (Educational Commission for Foreign Medical Graduates).
- 1982 - Israel Board of Internal Medicine.

5. RESEARCH INTERESTS:

- 1989-present Head of the Laboratory for Liver regeneration medicine, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.
- 1983-1985 Research in Liver Research Laboratory, University of Cape Town, South Africa. Liver Regeneration and specific growth factors.
- 1981-1983 Research in Lipid Research Laboratory, Rambam Medical Center, Haifa. Hyperlipidemia In Primary Biliary Cirrhosis.

6. TEACHING EXPERIENCE:

- 1998- present Bruce Rappaport Faculty of Medicine, Technion-Israel: Coordinator of the integrative Course of gastrointestinal and liver diseases.
- 1998- present TeAMS- Technion American Medical School Program: Coordinator of the ICM- Introduction to clinical medicine.
- 1986- present Course coordinator – Liver diseases for students in Internal medicine wards.
- 1986-1991 Rambam Medical Center, Haifa: Course coordinator, Internal Medicine for Primary Care Physicians.
- 1980- 1991 Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology: Instructor and coordinator, course in Internal Medicine.
- 1978-1981 Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology: Instructor, course on Physical Diagnosis to medical students.

7. TECHNION ACTIVITIES:

- 2011-Present Strategic Convergence Committee, Faculty of Medicine, Technion.
- 1999-2005 Animal House Committee, Faculty of Medicine, Technion.
- 1999-2001 Member of the MD thesis committee.
- 1993-1999 Admissions Committee, Faculty of Medicine, Technion.
- 1986-1996 Animal House Committee, Faculty of Medicine, Technion.

8. DEPARTMENTAL ACTIVITIES:

9. PUBLIC PROFESSIONAL ACTIVITIES:

- 2012- Member of the Israel committee for HCV treatment guide line.
- 2011- Head of appeal committee for liver transplantation at the ministry of health.
- 1996-2011 Member of the board of governors of the Israel foundation for liver disease.
- 2008- 2009 Member of "The Health Basket" committee of IMA.
- 1996-2007 Head of the Liver transplantation committee at the Israel council of transplantation.
- 1993-2005 Member of the Liver Transplant Committee advisory to Israel Transplantation Council (Since 1994, head of committee).
- 1996-2000 Member of the Council for Quality at Rambam Medical Center, and Head of a Quality Improvement project on pulmonary edema.
- 1997-1999 Chairman of the Israel association for the study of the liver.
- 1991-1993 Head, Medical Archives Committee, Rambam Medical Center.
- 1989-1993 Hospital Mortality Committee, Rambam Medical Center.

Reviewer of International Journals

- 1999 Journal of Hepatology
- 2001 Liver
- 2001 Journal Clin Endocrinol Metab
- 2003 Journal of Gastroenterol and Hepatol
- 2004 Journal of Anti Cancer Drugs
- 2006 Hepatology
- 2007 European Journal of Gastroenterol and hepatol
- 2008 Journal cell physiology
- 2008 Journal clin and lab investigation
- 2009 Journal of molecular and cellular med
- 2010 Journal of Histology and Histopathology
- 2010 Rambam Maimonides Medical Journal
- 2011 Histochemistry and Cell Biology

2011 DDS
2012 Journal of Laboratory Investigation
2012 Journal of International Hepatology

Editorial board:

2008 Liver International
2011 Current Tissue Engineering
2012 Editor of the Israeli Journal for Liver diseases (Herefuah Update).

10. MEMBERSHIP IN PROFESSIONAL SOCIETIES:

National:

- Israel Gastrointestinal Association.
- Israel Association for the study of the liver (IASL).
- Israel Association for Organ Transplantation.

International:

- European Association for the Study of the Liver.
- American Association for the Study of the Liver.
- International Liver transplantation association.
- International Association for the study of the liver

11. HONORS:

1992 American Physicians Fellowship and Dean of Faculty Award for Excellency in research.

12. GRADUATE STUDENTS:

PhD, and MSc

Finished

2004 Rubinstein Iris, PhD. Co-culture of hepatocytes and Kuppfer and Ito cells on biodegradable sponges for liver cell support. (with Prof. Smadar Cohen, primary supervisor, BGU).

2004 Shani Hagit, MSc. Enhancement of transplanted liver cell engraftment during liver regeneration in the rat. (Prof. Yaacov Baruch primary supervisor).

2007 Boyanjo Ilanit, MSc. Human embryonic stem cells differentiation during liver regeneration in the rat. (Prof. Yaacov Baruch primary supervisor).

2008 Helena Axelman, MSc. Enhancement of transplanted liver cell engraftment during liver regeneration in the rat, with vascular manipulations.(Prof. Yaacov Baruch primary supervisor).

Expected to finish

2010-2012 Omri Nayshool MSc. Hydrogel scaffolds for liver tissue bioengineering. (Prof. Yaacov Baruch primary supervisor).

MD thesis

1. Igal Peled, 1989: The effect of calcium channel blockers on liver regeneration in the rat. Supervisors
2. Shirley Neshet, 1990: Hepatitis C virus in liver cirrhotic patients in Israel.
3. Barak B, 1990: Sexual transmission of HCV infection. (Joint supervision with Prof. Ben-Porath).
4. Sigal Rubin, 1996: Amantadine in HCV Chronic liver disease. (Joint supervision with Dr. Assy Nimer and Prof. Rafael Enat).
5. Konofeniki Muriel, 2002: Pain mapping after liver biopsy to improve patients' care and compliance. (Joint supervision with Dr. Aisenberg A.).
6. Mayson Darawshi, 2012: Can histomorphometric findings predict response to antiviral therapy in patients with chronic HCV infection?
7. Nizar Higazi, 2013: Evaluation of early stage fibrosis in patients with chronic HCV infection using digital imaging.

Basic science

1. Nimer Assy, 1996: IGF-I generation test in patients with liver cirrhosis. (Joint supervisor with Z. Hochberg and T. Amit.).
2. Sabith Wissam, 1995: Long-term effect of growth factor-binding Factor on regenerating rat liver or parenchymal and non-parenchymal cells. (Joint supervisor with G. Shoshany.).
3. Ana Salomonov, 1995: Factors predicting response to interferon Treatment in Israeli patients with hepatitis C virus. (Supervision).
4. Krasik Ana, 1996: VEGF and the liver. Use of transfected Fibroblasts with VEGF gene in the nude mice model. (Supervision).
5. Prodjansky J, 1999: IGF-I generation test in patients with liver cirrhosis. (Joint supervision with Z. Hochberg and Assy Nimer).
6. Weitzman E, 2000: Detection of Sry- domain of the Y-chromosome as a marker of transplanted liver cells. (Supervision).
7. Armali Z, 2002: Diuresis with vassopressin in-patients with tense ascites. (Joint supervision with Dr. Eisenmam).
8. Weisbuch F. 2004, Liver tissue Bioengineering.
9. Farber Y, 2003: Correlation between Esophageal X-rays and UGIT endoscopy for the detection of varices in liver cirrhosis patients (Joint supervision with Prof. Eliakim).
10. Saadi T, 2008: Hepatocytes function within Biosynthetic polymers.
11. Bramnik Z, 2010: Transplantation of hepatocytes and biosynthetic hydrogel scaffolds, into rat's liver after 70% hepatectomy, the basis for liver tissue regeneration therapy.

12. Ori Kaplan, 2012: Intravascular liver tissue bioengineering.

13. RESEARCH GRANTS:

- 2008- Joint Inter departmental grant with Bioengineering, Technion-Israel Institute of Technology. Biosynthetic hydrogel scaffolds for liver tissue regeneration therapy. (25,000 IS). Prof. Baruch Y. (PI) and Dr. Seliktar D. (PI).
- 2006- Ministry of health research grant from Inheritance funds : Stem cell Transplantation (80,000 IS). Dr. Weitzman E. (PI), Prof. Baruch Y. (PI).
- 2002- Israel ministry of health (100,000 IS). Human stem cells in the SCID mice regenerating liver. (With Prof. Itzkovitz). (PI): Dr. Weitzman and Prof. Baruch.
- 2001- Mars-Pittsburgh fund (25,000\$). VEGF and hepatocytes transplantation. Prof. Y. Baruch (PI) and Prof. G. Neufeld.
- 2000- Ministry of health research grant from Inheritance funds: Liver cell transplantation (18,000 IS). Prof. Y. Baruch (PI).
- 1999- Israel ministry of health (60,000 IS). Tissue Bioengineering for liver failure supports. Prof. Y. Baruch (PI) and Prof. Smadar Cohen (PI) from B.G.U.
- 1999- Israel ministry of health (60,000 IS). Vasopressin in fluid retention in liver Cirrhosis and C.H.F. Dr.Eisenman (PI). Prof. Y. Baruch (PI).
- 1998- Niedersachsen- Technion grant (200 000 DM). Tissue Bioengineering for liver failure support. (Prof. Y. Baruch (PI) , prof. G. Spira (PI), Prof. Smadar Cohen (PI) and Prof. Giuliano Ramadori from Gottingen (PI))
- 1994- Joint grant from Israel Ministry of Health and Technion-Israel Institute of Technology: (15000 IS). Effect of ursodeoxycholic acid on cardiovascular system in liver cirrhosis (Prof. Y. Baruch (PI). In collaboration with Dr. N. Assy and Prof. A. Bomzon.
- 1990-1992 Israel Ministry of Health (15,000 IS). Liver regeneration and growth stimulation. Prof. Y. Baruch (PI), in collaboration with Prof. M. Fry, Dept. of Biochemistry. Technion).

14. SIGNIFICANT PROFESSIONAL PROJECTS:

- 2001 Efficacy and safety of budesonide capsules versus prednisone patients with diagnosis of active autoimmune hepatitis. A double randomized active controlled multi center phase III study (RAFA BUC-38).
- 2002 A Preliminary assessment of safety and antiviral activity of open-label Entecavir in subjects with chronic hepatitis B following monotherapy in other Entecavir trials (BMS AI463-901).
- 2003 Ribavirin with Peg interferon in chronic hepatitis C patients (ROCHE ML16837)
- 2003 Entecavir for subjects with chronic hepatitis B infection (BMS AI463-900).
- 2003 Long-term assessment of treatment outcomes with Entecavir and Lamivudine for chronic hepatitis B infection in patients who have enrolled in phase III Entecavir trials (BMS AI463-049).
- 2005 Randomized, Double-Blind, Multicenter study to compare the safety and efficacy of Virmidine to Ribavirin in treatment –naïve patients with chronic hepatitis C (VALIANT RNA003142-302).

- 2005 A Randomized, Double-Blind Trial of Telbivudine versus Lamivudine in adults with decompensated chronic hepatitis B and evidence of Cirrhosis (QUINTILES NV-02B-011).
- 2006 A Randomized Trial of Switching Antiviral Therapy from Lamivudine to Telbivudine. Continued Lamivudine Treatment in adults with Chronic Hepatitis B (QUINTILES NV-02B-019).
- 2006 A Double-Blind, Randomized, Multi-Centre, PhaseIIA parallel dose ranging study to assess the antifibrotic of GI26570 in HCV infected individuals who have failed standard antiviral therapy and who have documented hepatic fibrosis ISHAK grade 2-5 (GSK GI262570).
- 2006 A Multi-Center, Active-Controlled, Randomized, Open-Label Study to Evaluate the safety, Tolerability, and Efficacy of Albuferon Recombinant Human Albumin-Interferon Alfa Fusion Protein in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1 (PAREXEL_ALFR-HC-04).
- 2006 An open label trial of Telbivudine in adults with chronic hepatitis B previously treated in Telbivudine studies (QUINTILES NV-02B-022).
- 2008 A phase II randomized, placebo-controlled study to evaluate the safety and efficacy of MK-7009 administered concomitantly with Pegylated Interferon and Ribavirin for 28 days in treatment naïve patients with chronic hepatitis C infection (MSD protocol 007).
- 2009 A randomized, double-blind, placebo-controlled phase III trial of telaprevir with pegylated interferon alfa 2a and ribavirin in subjects with genotype 1 chronic hepatitis C infection who did not achieve sustained virologic response following prior treatment with pegylated interferon plus ribavirin (J & J VX950-TiDP24).
- 2009 A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa-2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trial (MSD 028-00).
- 2009 A phase II randomized, placebo-controlled study to Evaluate the safety and Tolerability, and Efficacy of different Regimens of MK-7009 When Administered concomitantly with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients With chronic Genotype 1 Hepatitis C Virus Infection (MSD 019-00).
- 2009 A phase IIB, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of treatment regimen including PegIFN alfa-2a and ribavirin in HCV genotype 1 infected subjects who failed to respond or relapsed following at least 1 course of PegIFN alfa-2a/b and RBV therapy (J & J TMC-435-TiDP16-C206).
- 2009 An Open-Label, multi-center study evaluating the efficacy, safety and tolerability of extended treatment of Pegasys in combination with Copegus in genotype 1,2 and 3 chronic hepatitis C patients defined as slow responders/non RVR (ROCHE ML21778).
- 2010 A Phase 3, randomized, double-blind, placebo-controlled trial of 48 weeks of GS-9190 in combination with Peginterferon Alfa 2a and Ribavirin in previously untreated subjects with genotype 1 chronic hepatitis C virus infection (PPD – GILEAD GS-US-196-0116).
- 2010 A Phase II, multicenter, randomized, double blind, placebo controlled study on the effect of Aramchol on liver triglyceride concentration in patients with steatosis due to NAFLD or NASH (Galmed Aramchol 003)
- 2010 An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP24-C216 trial who failed therapy for virologic reasons (Tibotec VX-950-TiDP24-C219).

Pharmacogenomic analysis of Blood samples to Identify Host Genomic profiles that segregate responders from Non-responders following treatment with Peg-Interferon and Ribavirin in HCV infected subjects -genotype 1 (CATO PJMR0012106).	2010
A Phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 hepatitis C (Transgene TG4040).	2010
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsules plus placebo in the treatment of primary biliary cirrhosis (Dr. Falk Pharma GmbH BUC-56/PBC).	2011
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 Hepatitis C Virus Infection (Merck & CO., MK-5172).	2011
A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN and Ribavirin in treatment-naïve and prior relapser subjects with genotype 1 chronic hepatitis c and IL28B cc genotype (Vertex Pharmaceuticals VX11-950-114).	2011
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel group study, with an open label extension to evaluate the efficacy, safety and Pharmacokinetics of E5501 in subjects with chronic hepatitis c virus related Thrombocytopenia who are potential candidates for antiviral treatment (Eisai Inc. E5501).	2012
A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed after previous interferon-based therapy (Tibotec. TMC435HPC 3007).	2012
Double-blind, randomized, placebo controlled study to assess the safety and the efficacy of a sublingual administration of Flumazenil to reverse the effect of hypnotic drugs (Zolpidem or Brotizolam) in healthy adults (Coeruleus Ltd. CRLS001).	2012
A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection (Bristol-Myers Squibb AI452-028).	2012
A Phase II Randomized, Partially Blinded, Pilot Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Treatment-Naïve (TN) Patients with Chronic Genotype 1 (GT 1) Hepatitis C Virus Infection (Merck & CO. Inc. MK-5172-034).	2012
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects (Merck & CO. Inc. MK 3034-040).	2012
A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial (Merck & CO. Inc. MK 5172-017).	2012
A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection. (Merck & CO. Inc. MK	2012

5172-039).

A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III). (Abbott M13-961).	2012
A Phase 3, Multicenter, Randomized, Active-Controlled study to investigate the safety and efficacy of PSI-7977 and ribavirin for 12 weeks compared to Pegylated interferon and Ribavirin for 24 weeks in treatment Naïve patients with chronic genotype 2 or 3 HCV infection (Quintiles P7977-1231).	2012
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (Merck & CO. Inc. MK 5172-035).	2013
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or Relapsed on Treatment with Peginterferon Alfa and Ribavirin (Bristol-Myers Squibb AI452-020).	2013
A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 (Merck & CO. Inc. MK 5172-047).	2013
A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease (Merck & CO. Inc. MK 5172-052).	2014
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure (Eisai Inc. E5501-G000-311)	2014
A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Direct Acting Antiviral Therapy (Merck & CO. Inc. MK5172-048).	2014
A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are Co-Infected with HIV (Merck & CO. Inc. MK5172-061).	2014
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy (STOP-HE Study, OCR002-HE209).	2014
Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH, Aramchol05)	2014
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-50/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I, M14-423).	2014
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection (MK3682-012).	2014
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in	2014

15. PUBLICATIONS

M.D. Thesis

- Baruch Y.** Disappearance of Q wave from electrocardiogram of patients after myocardial Infarction. M.D. thesis, Technion-Israel Institute of Technology, Haifa, 1977. 1.

Original Articles

Basic Research

- Baruch Y**, Brook JG, Eidelman S, Aviram M. Increased concentration of high density lipoprotein in plasma and decreased platelet aggregation in primary biliary cirrhosis. *Atherosclerosis* 53:151-162, 1984. 2.
- Yeshurun D, Aviram M, Barak C, **Baruch Y**, Brook JG. Effect of prolonged fasting on lipid and lipoprotein concentrations in markedly obese patients. *Nutr Rep Int* 34:613-619, 1986. 3.
- Baruch Y**, Frith, Kirsch RE. Twenty-two percent partial hepatectomy: in vivo rat model for the study of liver regeneration. *J Hepatol* 12:316-320, 1991. 4.
- Liang TJ, **Baruch Y**, Ben-Porath E, et al. Hepatitis B and hepatitis C virus infection in patients with idiopathic liver disease. *Hepatology* 13:1044-1051, 1991. 5.
- Baruch Y**, Amit T, Enat R, Hertz P, Youdim MBH, Hochberg Z. Growth hormone binding protein in liver cirrhotic patients. *J Clin Endocrinol Metab* 73: 777-781, 1991. 6.
- Baruch Y**, Enat R, Gershoni-Baruch R, et al. Anamnestic response to hepatitis B vaccine in Non-Alcoholic liver cirrhosis patients with and without HBV-DNA. *Am J Gastroenterol* 87:613-616, 1992. 7.
- Amit T, Hartman K, Shoshany G, **Baruch Y**, Youdim MBH, Hochberg Z. The turnover of Growth hormone (GH) binding protein and GH receptor in rabbit and rat. *Mol Cell Endocrine* 94:149-154, 1993. 8.
- Baruch Y**, Amit T, Enat R, Shoshany G, Youdim MBH, Hochberg Z. Growth hormone-binding protein in partially hepatectomized rats. *Horm Res* 40:173-177, 1993. 9.
- Gilhar A, Enat R, **Baruch Y**. HLA-DR-positive Langerhans cells in liver cirrhosis and Immunosuppressed liver-transplanted patients. *Acta Dermato-Venereol* 74:93-94, 1994. 10.
- Baruch Y**, Shoshany G, Neufeld G, Enat R. Basic fibroblast growth factor is hepatotropic for rat liver in regeneration. *J Hepatol* 23:328-332, 1995. 11.
- Assy N, Hochberg Z, Amit T, Enat R, **Baruch Y**. Growth hormone stimulated insulin-like growth factor I and insulin binding protein 3 in liver cirrhosis. *J Hepatol* 27: 797-802, 1997. 12.
- Assy N, Hochberg Z, Enat R, **Baruch Y**. Prognostic value of of GH-stimulated IGF-I and IGFBP-3 in compensated and decompensated liver cirrhosis. *Dig Dis Sci*. 43:1317-1321, 1998. 13.
- Baruch Y**, Assy N, Amit T, Krivoy N, Strikovsky D, Shen-Orr Z Hochberg Z. Spontaneous Pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients. *J Hepatol* 29: 559-564, 1998. 14.
- Assy N, Spira G, Paizi M, Shankar L, Kraizer Y, Cohen T, Neufeld G, Enat R, **Baruch Y**. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial

Hepatectomy in rats. *J Hepatol* 30: 911-915, 1999.

- Weitzman E, Shenkar L, Shoshany G, Kasinetz L, Gershoni- Baruch R, **Baruch Y**. 16.
Detection of transplanted Hepatocytes by PCR analysis of the SRY domain on the Y chromosome. *Transplant Proceed* 32: 721-723, 2000.
- Baruch Y**, Neubauer K, Shenkar L, Wilfling T, Ritzel A, Boucholt M, Ramadori G. 17.
Von willebrand factor (vWf) expression and plasma levels after partial hepatectomy (PHP) in the rat. *J Hepato* 37 (4): 471-477, 2002.
- Neubauer K, **Baruch Y**, Lindhorst A, Saile B, Ramadori G. Gelsolin gene expression is upregulated 18.
in damaged rat and human livers within non-parenchymal cells and not in epatocytes. *Histochem Cell Biol* 120: 265-275, 2003.
- Perets A, **Baruch Y**, Shoshany G, Weisbuch F, Neufeld G, Cohen S. 19.
Enhancing the vascularization of 3-D porous alginate scaffolds by incorporating controlled release bFGF microspheres. *J Biomed Mater Res* 65A:489-497, 2003.
- Shani H, Tsiperson V, Shoshany G, Veitzmen E. Neufeld G, **Baruch Y**. 20.
The effect of VEGF on hepatocyte engraftment after intrasplenic cell transplantation in the rat. *Cell transplantation* 14:49-57, 2005.
- Vadasz Z, Kessler O, Akir G, Gengrinovitch S, Kagan H.M, **Baruch Y**, Ben Izhak O, and Neufeld G. 21.
The role of lysyl oxidase related protein-1 in the pathogenesis of liver diseases associated with copper accumulation. *Journal of Hepatology*. 43:499-507, 2005.
- Tsiperson V, Goldshmidt O, Ilan N, Shoshany G, Vlodayvsky I, Veitzman E and **Baruch Y**. 22.
Heparanase enhances hepatocytes engraftment in partially hepatectomysed rats. *Tissue Engineer*. 14:449-455, 2008.
- J. Carmel, A. Arish, G. Shoshany and **Baruch Y**. 23.
Heparanase accelerates proliferation of both hepatocytes and sinusoidal endothelial cells after partial hepatectomy despite IL-6 and TNF-a down regulation. *Experimental and Molecular Pathology*. 92: 202-209, 2012.
- Saadi T, Nayshool O, Carmel J, Ariche A, Bramnik Z, Mironi-Harpaz I, Seliktar D, **Baruch Y**. 24.
Y. Cellularized biosynthetic micro-hydrogel polymers, for intravascular liver tissue regeneration therapy. *Tissue Eng Part A*. 20: 2850-2859, 2014.

Clinical Descriptive Research

- Markiewicz W, Monakier I, Brik A, **Baruch Y**, Hir J. Clinical echocardiographic correlations in 25.
pericardial effusion. *Eur Heart J* 3:260-266, 1982.
- Enat R, Ben-Porath E, Joffe B, **Baruch Y**, Lichtig C. Ethnic differences in the incidence of 26.
postnecrotic cirrhosis in Israel: correlation with hepatitis B virus serological markers. *Am J Gastroenterol* 78: 656-660, 1983.
- Gershoni-Baruch R, **Baruch Y**, Viener A, Lichtig C. Fechtner syndrome: clinical and genetic 27.
Aspects. *Am J Med Genet* 31:357-367, 1988.
- Baruch Y**, Ben-Arie Y. Kerner H, Lorber M, Best L-A, Gershoni-Baruch R. Giant lymph node 28.
Hyperplasia (Castleman's disease): a clinical study of eight patients. *Postgrad Med J* 67:366-370, 1991.
- Blumenfeld Z, Enat R, Brandes JM, **Baruch Y**. Dysfunctional bleeding in women after liver 29.
Transplantation: use of GnRH analogue. *Fertil Steril* 57:1121-1123, 1992.

- Baruch Y**, Engel A, Eyal A, Enat R. Transjugular liver biopsy in patients with bleeding tendency. *Harefuah* 125:461-463, 1993 (in Hebrew). 30.
- Modan B, Shpilberg O, **Baruch Y**, Sikuler E, Anis E, Ashur Y, Chetrit A, Luxenburg O, Rosenberg E, Rosenthal N, Sadetzki S, Benaim H, Eckstein H, Shouval D. The need for liver Transplantation: a nationwide estimate based on consensus review. *Lancet* 346:660-662, 1995. 31.
- Ilan Y, Galun E, Nagler A, **Baruch Y**, Livni N, Shouval D, Tur-Kaspa R. sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation. *Liver Transpl Surg* 2:206-210, 1996. 32.
- Assy N, Blumenfeld Z, Berkovitz D, Nave Y, Kramsky R, Rosenthal E, Enat R, **Baruch Y**. Long term follow up of liver transplant patients in a non liver transplantation Center. *Transplant Proceed* 29:2664-2666, 1997. 33.
- Baruch Y**, Assy N, Kramsky R, Enat R. Safety of conversion from sandimmune asopressin to asopressin Neoral in stable liver transplant patients. *Transplant Proceed* 30: 1852-1853, 1998. 34.
- Hashmonai M, Kopelman D, Asalia A, Klein Y, Bahous H. and **Baruch Y**. Extensive liver Resections: report of 72 cases. *Harefuah* 135: 409-413, 1998. 35.
- Hoffman R, Assy N, Brenner B. and **Baruch Y**. Factor five Leiden mutation and Budd Chiari Syndrome report of six patients. *Liver transplant and surg* 5:96-100, 1999. 36.
- Baruch Y**, Assy N, Weisbuch F, Reisner S Gaitini D, Blendis L, Enat R, Bomzon A. A pilot Study on the hemodynamic effect of short term ursodeoxycholic acid therapy in patients with Stable liver cirrhosis. *Amer J Gastroenterol* 94: 3000-3004, 1999. 37.
- Eisenman A, Armali Z, Enat R, Bankir L, **Baruch Y**. Low-Dose 12asopressin reverse renal Shut down both in patients with the hepatorenal syndrome and in patients with end stage heart Failure. *J Intern Med* 246: 183-190, 1999. 38.
- Paradis K et al (multiple authors). Prospective, multi-center study of patients treated with living Pig tissue: is there an evidence of cross species transmission of porcine endogenous retrovirus? *Science* 285: 1236-1241, 1999. 39.
- Ben-Ari Z, Samuel D, Zemel R, **Baruch Y**, Gigou M, Sikuler E, Tur-Kaspa R. Non A to G Fulminant viral hepatitis leading to liver transplantation. *Arch Int Med* 160: 388-392, 2000. 40.
- Shlomi B, Machtei EE, Oettinger-Barak O, Peled M, Ardekian L, Laufer D, **Baruch Y**. Alveolar bone height in patients after liver transplantation. *Transplant Proceed* 32: 718-720, 2000. 41.
- Ben-Ari Z, **Baruch Y**, Tur-Kaspa R, Fainaru M. Basal and post-methionine serum Homocysteine and lipoprotein abnormalities in-patients with primary biliary cirrhosis. *J Invest Med* 49: 325-329, 2001. 42.
- Oettinger-Barak O, Barak S, Ardekian L, **Baruch Y**, Peled M, Laufer D, Machtei EE. Periodontal changes in liver cirrhosis and post liver transplantation patients I: Clinical changes. *J Periodontal* 72: 1236-1240, 2001. 43.
- Barak S, Machtei EE, Oettinger-Barak O, Peled M, Ardekian L, Laufer D, **Baruch Y**. Alveolar bone height in patients after liver transplantation. *Transplant Proceed*, 32: 718-720, 2000. 44.
- Segal E, **Baruch Y**, Kramsky R, Raz B, Ish-Shalom S. Vitamin D deficiency in liver transplant patients in Israel. *Transplant Proceed* 33: 2955-2956, 2001. 45.
- Nakhoul F, Gelman R, Green J, Khankin E, **Baruch Y**. Lamivudine therapy for severe acute hepatitis B virus infection after renal transplantation: case report and literature review. *Transplant* 46.

- Proceed 33: 2948-2949, 2001.
- Oettinger-Barak O, Barak S, Ardekian L, **Baruch Y**, Peled M, Krivoy N, Laufer D, Machtei EE. 47.
Periodontal changes in liver cirrhosis and post liver transplantation patients II: Radiographic changes. *J Periodontol* 73 (3): 313-316, 2002.
- Segal E, **Baruch Y**, Kramsky R, Raz B, Tamir A, Ish-Shalom S. 48.
Predominant Factors Associated with Bone Loss in Liver Transplant Patients – after prolonged post transplantation period. *J. Clinical Transplantation* 17: 13-19, 2003.
- Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaitini D, **Baruch Y**. 49.
Prevalence and Characteristics of Pain Induced by Percutaneous Liver Biopsy. *Anesth Analg* 96:1392-1396, 2003.
- Baruch Y**, Neubauer K, Wilfing T, Lorf T, Borcholt M, Ramadori G. Von-Willebrand 50.
Immunostaining and mRNA expression in acute and chronic liver disease. *Hepatogastroenterology* 51: 684-688, 2004.
- Gaitini D, **Baruch Y**, Ghersin E, Kerner H, Shalem B, et al. Feasibility study of ultrasonic fatty liver 51.
biopsy: texture vs. attenuation and backscatter. *Ultrasound Med Biol.* 30:1321-1327, 2004.
- Farber E, Fisher D, Eliakim R, Beck-Razi N, Angel A, Veitsman E, Chermesh I, 52.
Yassin C, Gaitini D, Libas M, Soboh S, **Baruch Y**. Barium Esophagogram (BE) versus Upper
Endoscopy (EGD) for the screening of esophageal varices (EV) in patients with compensated cirrhosis
– a blinded prospective study. *Radiology*, 237:535-540, 2005.
- Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow 53.
WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HbeAg-
Positive Chronic Hepatitis B Study Group (**Baruch Y**, part of study group). Peginterferon Alfa-2a,
lamivudine, and the combination for HbeAg-positive chronic hepatitis B. *N Engl J Med* 352:2612-
2695, 2005.
- Gaitini D, Lederman M, **Baruch Y**, Ghersin E, Veitsman E, Kerner H, Shalem B, Yaniv G, Sarfaty C, 54.
Azhari H. Computerised analysis of liver texture with correlation to needle biopsy. *Ultraschall
Med.*26:197-202, 2005.
- Zalts R, Hayek T, **Baruch Y**, Nakhoul F, Miller B. Vogt-Koyanagi-Harada syndrome 55.
associated with renal failure: a case report. *J Nephrol.* 19:225-228, 2006.
- Lurie Y, Landau D, Blendis L, **Baruch Y**, Veitsman E, Ackermann Z, Halpern Z, Zelberger-Sagie, 56.
Oren R. Acute hepatitis C in Israel – A Predominantly Iatrogenic Disease?
J Gastroenterol Hepatol. 22:158-164, 2007.
- Katz D., Cohen M., Kramski R. and **Baruch Y**. Stress in family caregivers of liver transplant 57.
recipients. *Progress in Transplantation.* 17:48-53, 2007.
- Oettinger-Barak O, Segal E, Machtei EE, Barak S, **Baruch Y**, Ish-Shalom S. Alveolar bone loss in 58.
liver transplantation patients: relationship with prolonged steroid
treatment and parathyroid hormone levels. *J Clin Periodontol* 34: 1039–1045; 2007.
- Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, and **Baruch Y**. 59.
Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction.
J Hepatology, 49:34-42, 2008.
- Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, 60.
Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison
JG; **ACHIEVE-1 Study Team, (Baruch Y, part of study Team)**. Albinterferon Alfa-2b was not
inferior to pegylated interferon- α in a randomized trial of patients with chronic hepatitis C virus

genotype 1. *Gastroenterology*.139:1257-1266, 2010.

- Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; **ACHIEVE-2/3 Study Team, (Baruch Y, part of study Team)**. Albinterferon Alfa-2b was not inferior to pegylated interferon- α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. *Gastroenterology*. 139: 1267-1276, 2010. 61.
- R. Kramskay, A. Tansky, E. Eisenberg, E. Veitsman and **Y. Baruch**. Prophylactic analgesia before percutaneous liver biopsy (Clinical comparative study). *European J Gastroenterol Hepatol*. 23: 782-786, 2011. 62.
- Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; **ADVANCE Study Team (Baruch Y, part of study Team)**. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med*. 23; 2405-2416, 2011. 63.
- Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; **REALIZE Study Team (Baruch Y, part of study Team)** .Telaprevir for retreatment of HCV infection. *N Engl J Med*. 23: 2417-2428, 2011. 64.
- E. Veitsman, E. Shahar, G. Hassoun, M. Lorber , R. Kramskay, C. Maor , S. Pollack and **Y. Baruch**. Outcome of treatment with Peg-Interferon and Ribavirin in HIV-HCV co-infected patients: "REAL LIFE" single center experience. *Harefuah*. 151(12):684-687, 721, 720, 2012. 65.
- E. Machtei, M. Falah, O. Oettinger-Barak, **Y. Baruch** and J. Horwitz. Periodontal status in post liver transplantation patients – 10 years follow-up. *Quintessence Int*.43(10):879-885, 2012. 66.
- M. Woynarowski, A. Nemeth, **Y. Baruch**, S. Koletzko, M. Melter, B. Rodeck, C. Strassburg, M. Pröls, M. Woźniak, MP. Manns and the European AIH-BUC-Study Group. Budesonide versus prednisone in combination with azathioprine for the treatment of autoimmune hepatitis in adolescents: results of an international randomized trial. *J Pediatr*.163(5):1347-1353, 2013. 67.
- Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, **Baruch Y**, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. *N Engl J Med*. 22;370(21):1983-1992, 2014. 68.
- Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, **Baruch Y**, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The Combination of MK-5172, Peginterferon, and Ribavirin is Effective in Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. *Gastroenterology*.147(2):366-376, 2014. 69.

Case Reports

- Baruch Y**, Levi Y, Brook JG, Kleinhaus U, Hashmonai M. Splenic abscess diagnosed by the aid Of abdominal computerized tomography: report of 2 cases. *Br J Surg* 68:137-138, 1981. 70.

- Levi Y, Aviram M, **Baruch Y**, Brook JG. Familial hypercholesterolemia and Hyperlipoproteinemia, type III. *Harefuah* 106:565-566, 1984 (in Hebrew). 71.
- Enat R, **Baruch Y**, Malberger E, Caftori I. Diagnosis of parathyroid cyst with hormonal activity. *Harefuah* 103:399-400, 1987 (in Hebrew). 72.
- Baruch Y**, Levi Y, Goldstein D, Monichor M, Eidelman S. Massive haematemesis: presenting Symptoms of cystadenocarcinoma of the pancreas. *Postgrad Med J*, 65:42-44, 1989. 73.
- Naschitz JE, Enat R, Yeshurun D, Eisenberg D, **Baruch Y**, Bassan L, Misselevitch I, Boss H. Massive subcapsular fibrosis of the liver: ultrasonic and computerized tomographic characteristics. *J Clin Gastroenterol* 13:470-474, 1991. 74.
- Baruch Y**, Weiner N, Ronen N, Enat R, Blumenfeld Z. Pregnancy after liver transplantation. *Int J Gynecol Obstet* 41:273-276, 1993. 75.
- Eisenman A, **Baruch Y**, Shechter Y, Oren I. Blood exchange: a rescue procedure for complicated Malaria falciparum. *Vox Sang* 68:19-21, 1995. 76.
- Baruch Y**, Weitzman E, Markiewicz W, Eisenman A, Eid A, Enat R. Severe fluid retention and cardiomyopathy in a liver transplant patient on FK506. *Transplant Proceed.* 28: 2250-2251, 1996. 77.
- Assy N, Rosenthal E, Hazani A, Etzioni A, **Baruch Y**. Human parvovirus B19 infection associated with idiopathic thrombocytopenic purpura in a child following liver transplantation. *J Hepatol* 27: 934-936, 1997. 78.
- Edoute Y, **Baruch Y**, Lachter J, Furman E, Bassan L, Assy N. Severe cholestatic jaundice induced by Epstein-Barr virus infection in the elderly. *J Gastroenterol Hepatol* 13: 821-824, 1998. 79.
- Ben Ari Z, Broida E, Monselise Y, Kazatsker A, **Baruch Y**, Pappo O, Skappa E, Tur-Kaspa R. Syncytial giant-cell hepatitis due to autoimmune hepatitis type III (LKM1+) presenting as subfulminant hepatitis. *Am J Gastroenterol* 95: 799-801, 2000. 80.
- Armalı Z, Bergman R, Bassan L and **Baruch Y**. Skin granuloma; unusual presentation of Recurrence of primary biliary cirrhosis after liver transplantation. *Transplant Proceed* 32: 717, 2000. 81.
- Veitsman E., Yigla M., Thaler I. and **Baruch Y**. Two successful pregnancies in a patient with advanced liver cirrhosis and hepatopulmonary syndrome. *Gastroenterology and Hepatology*, 3: 546-550, 2007. 82.
- Saadi T, Rosenbaum H, Veitzman E. and **Baruch Y**. Gaucher's disease Type I - a disease masked by the presence of abnormal laboratory tests common to primary liver disease. *European Journal of Gastroenterology & Hepatology. Eur J Gastroenterol Hepatol* 83.
- Saadi T, Khoury S, Veitsman E, **Baruch Y**, Raz-Pasteur A. Spontaneous bacterial peritonitis with a very high leukocyte count in ascitic fluid caused by haemophilus influenza. *Int J Gen Med.* 19;6:689-691, 2013. 84.
- Saadi T, Waterman M, Yassin H, **Baruch Y**. Metformin-Induced Mixed hepatocellular and cholestatic hepatic injury – case report and literature review. *Int J Gen Med.* 19;6:703-706, 2013. 85.
- Saadi T, Brun R, Chowars Y, **Baruch Y**, Waterman M. Recurrent small intestinal ileus 86.

secondary to valsartan treatment. *J Clin Gastroenterol*.48(5):462-463, 2014.

Safadi R, Konikoff F, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R, and the FLORA Group. The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, 2014. 87.

Review papers

Baruch Y, Aviram M, Brook J.G. hyperlipidemia in liver disease. *Harefuah* 104:61-64, 1983 (In Hebrew). 88.

Baruch Y, Eidelman S. The treatment of biliary cirrhosis. *Harefuah* 106:186-187, 1984 (In Hebrew). 89.

Baruch Y, Engel A, Enat R. Transjugular liver biopsy: how and when. *Harefuah* 119:338-339, 1991 (In Hebrew). 90.

Baruch Y, *Medicine Oncology*, Forum Media, A. Kotten ed. p. 260-261, May 2008 (In Hebrew). 91.

Makhoul B., **Baruch Y**. Autoimmune Hepatitis, diagnosis and treatment. *Harefuah update Gastroenterology*, vol 1:33-38, 2011 (In Hebrew). 92.

Sikuler E, Ackerman Z, Braun M, **Baruch Y**, Bruck R, Safadi R, Shlomai A, Ben-Ari Z; Guidelines for diagnosis and management of cirrhotic ascites and its complications. The Israeli Association for the Study of the Liver. *Harefuah*.151(12):705-8, 719, 2012 (In Hebrew). 93.

Zuckerman E, Safadi R, Oren R, Shibolet O, **Baruch Y**, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver. *Harefuah*. 151(12):709-14, 719, 2012 (In Hebrew). 94.

Books and book chapters

Ivanetich K, Thumser AEA, Ziman MR, **Baruch Y**, Kirsh RE. Liver injury and regeneration. In: Arias IM, Frenkel M, Wilson JHP (eds). *The Liver Annual* No. 5. Elsevier, Amsterdam, pp 71-115, 1985. 95.

Baruch Y, Brandes JM, Berk PD. Bilirubin metabolism, diseases of altered bilirubin metabolism, And pregnancy. In: *Medical, Surgical, and Gynecologic Complications of Pregnancy*, 5th ed. Williams & Wilkins, Baltimore, chap. 53, 863-902, 1991. 96.

Oettinger-Barak O, Barak S, **Baruch Y** and Machtei EE. Periodontal Status of Liver Cirrhosis and Post Transplantation Patients. In "Progress in Liver Cirrhosis Research". Nova Science Publishers, Inc. 2005. 97.

Baruch Y. Liver diseases in the elderly. In "The gastrointestinal tract in the aged". Stephen Malnick, Ehud Melzer Sari Tal, Eds. NOVA Publishers 2011. 98.

Baruch Y. The Liver Vascular Bed for Tissue Engineering. In "Regenerative Medicine and Tissue Engineering; From Cells to Organs". InTech - Open Access Publisher, D. Eberli editor, 449-462, 2011. 99.

Letters to the Editor

- Edoute Y, Kaplan J, Ben-Haim SA, **Baruch Y**. Haemoperitoneum induced by fine-needle aspiration of liver in patients with disseminated intravascular coagulation. *Lancet* 339:121-122, 1992. 100.
- Baruch Y**, Ben-Porath E, Enat R. Immunoprophylaxis with hepatitis B immunoglobulin after Liver transplantation: an economical approach. *J Hepatol* 20:153-154, 1994. 101.
- Krivoy N, Azam M, **Baruch Y**, Elroi G. Severe cholestasis due to oral hypoglycemic drug. *Diabetes care* 19:385-386, 1996. 102.
- Modan B, **Baruch Y**, Sikuler E, Shouval D. Need for liver transplantation. *Lancet* 348: 62-63, 1996. 103.
- Baruch Y**, Sikuler E., International ascites club – guidelines for the treatment of ascites. *Harefuah* 138: 903-904, 2000. 104.
- Hoffman R, Mahajana A, Agmon P, **Baruch Y**, Brenner B. Successful use for recombinant activated factor VII (Novoseven) in controlling severe intra abdominal bleeding after liver needle biopsy. *Thromb Haemost* 87:346-347, 2002. 105.

Editorials:

- Baruch Y**. The liver: a large endocrine gland. *J Hepatology* 32: 505-507, 2000. 106.

16. CONFERENCES:

Organizing committee of international medical and national conference

- First joint Spanish-Israeli meeting on liver and biliary diseases, Jerusalem, November 1991. 1.
- European Association for the Study of the Liver, Jerusalem, 1996. 2.
- First Israeli conference on HIV-HCV co-infection, Tel-Aviv, May 2004. 3.

Plenary or invited talks

- HBeAg negative chronic hepatitis B. BMS satellite symposium. EASL, Berlin, April 2004. 1.
- Hydatid liver disease. World Congress of Gastroenterology, Montreal, September 2005. 2.

Abstracts

- Yeshurun D, Aviram M, Barak K, **Baruch Y**, Brook JG. The effect of prolonged fasting on Lipoprotein concentration and composition in obese women. *Isr J Med Sci* 18:538, 1982. 1.
- Baruch Y**, Aviram M, Eidelman S, Brook JG. Dyslipoproteinemia in patients with primary Biliary cirrhosis. Sixth International Symposium on Atherosclerosis, Berlin, June 1982. 2.
- Aviram M, **Baruch Y**, Viener A, Brook JG. Platelet aggregation in hypercholesterolemia: A comparison between familial hypercholesterolemia and primary biliary cirrhosis. Third International Austrian Atherosclerosis Conference, Vienna, April 1983. 3.
- Baruch Y**, Aviram M, Brook JG. Increased plasma high-density lipoprotein in patients with Primary biliary cirrhosis. Twenty-fourth International Conference on the Biochemistry of lipids, Toulouse, France, September 1983. 4.
- Baruch Y**, Terblanche J, Kirsch RE. Hepatic regenerative factor. *S Afr Med J* 65:1024-1025, 5.

1984.

- Baruch Y.** Liver regeneration. In: Kirsch RE, Kruskal J, Csomos S, Terblanche J (eds). 6.
Liver Update: Proceedings of an International Symposium on Liver Physiology and Disease,
Vol. 2. Balliere Tindall, Cape Town, pp 121-122, 1985.
- Baruch Y**, Enat R, Gershoni-Baruch R, Ben-Porath E. Can booster effect of HBV vaccine given 7.
To cirrhotic patients identify previous infection with hepatitis B virus?
J Hepatol 7 (suppl 1): 593, 1988.
- Liang TJ, Ben-Porath E, Enat R, **Baruch Y**, Rimon N, Brown NV, Blum HE, Wands JR. 8.
Detection of hepatitis B-related virus in-patients with idiopathic liver disease. Annual meeting
Of the American Association for the Study of Liver Diseases, Chicago, October 1989.
- Baruch Y**, Liang TJ, Enat R, Rimon N, Wands JR, Ben-Porath E. Anamnestic immunologic 9.
Response to HBV vaccine in cirrhotic patients. International Symposium on Viral Hepatitis and
Liver Disease, Houston, Texas, April 1990.
- Hochberg Z, **Baruch Y**, Bick T, Hertz P, Amit T. Common expression and regulation of the 10.
Growth hormone receptor and GH binding protein in human and rat.
Twenty-ninth meeting of ESPE, Vienna, September 1990.
- Baruch Y**, Amit T, Enat R, Hochberg Z. Growth hormone-binding protein in the evaluation of 11.
Liver cirrhotic patients. J Hepatol (Suppl 2), 11:S73, 1990.
- Blumenfeld Z, **Baruch Y**, Brandes JM. New applications for GnRH analogues: dysfunctional 12.
Bleeding in women after liver transplantation and endometrial hyperplasia. Second International
Symposium on Analogues in Cancer and Human Reproduction, Geneva, November 1990.
- Baruch Y**, Blumenfeld Z, Brandes JM, Enat R. Dysfunctional bleeding in women after liver 13.
Transplantation and endometrial hyperplasia: use of GnRH analogue. International Meeting on
Transplant Monitoring, Jerusalem, June 1991.
- Baruch Y**, Enat R, Neufeld G. The effect of basic fibroblast growth factor (Bfgf) on liver 14.
Regeneration after partial hepatectomy. J Hepatology 13:S95, 1991.
- Baruch Y**, Neshet S, Ben-Porath E, Enat R. Incidence of anti-HCV in patients with chronic 15.
liver Disease in Israel. Fifteenth world congress of the Israel Medical Association, Jerusalem,
November 1991.
- Baruch Y**, Diab S, Blumenfeld Z, et al. The Rambam experience with post liver transplantation 16.
Care. First joint Spanish-Israeli meeting on liver and biliary disease, Jerusalem, April 1992.
- Baruch Y**, Amit T, Enat R, Shoshany G, Hochberg Z. The role of the liver in determining 17.
GH-binding protein. J Hepatol 16(suppl 1):S65, 1992.
- Baruch Y**, Assy N, Amit T. IGF-BP3 and IGF-I generation following growth hormone 18.
Stimulation as a liver endocrine reserve test. Hepatology 20:330A, 1994.
- Baruch Y**, Assy N, Reisner S, Blendis LM, Berry E, Enat R, Bomzon A. Plasma antioxidant 19.
Activity (PTAA) and cardiovascular (CVS) function following UDCA treatment in PBC.
J Hepatol 23:209, 1995.
- Eisenman A, Armali Z, Enat R, **Baruch Y**. Low dose Vassopressin (LDVP) reverses renal 20.
Shut-down both in patients with hepatorenal syndrome and in those with end stage heart failure.
J Hepatol; 98: 1997.
- Baruch Y**, Ben-Porath E, Salomonov A, Heidi S, Enat R, Lapidot A, Rimon N, 21.
Satinger Y, Weisbuch F and Baruch Y. Is the andomize use of Interferon to treat

chronic HCV infection in Israel is justified. *J Hepatol*; 157, 1997.

- Baruch Y**, Krasik A, Shoshany G, Shenkar L, Assy Y, Paizi M, Kraizer Y, Spira G. 22.
Vascular endothelial growth factor (VEGF) promotes parenchymal liver cell growth in Vivo.
EASL, Lisbon April 1998.
- Peretz A, **Baruch Y**, Spira G and Cohen S. Fabrication of alginate composite containing VEGF 23.
To enhance scaffold vascularization. Los-Angeles June 1998.
- Assy Y, Pruzansky Y, Gaitini D, Hochberg Z, Enat R, **Baruch Y**. Changes in insulin-like 24.
Growth factor-I release after GH administration in patients with different grades of liver
Cirrhosis. *Hepatology*, abs. 889: 1998.
- Baruch Y**, Neubauer K, Wilfing T, Lorf T, Borcholt M, Ramadori G. 25.
Von-Willebrand Immunostaining and mRNA expression in acute and chronic liver disease.
Hepatology 1998, abs. 1887.
- Ben Ari Z, **Baruch Y**, Grenberg A, Levi N, Tur-Kaspa R. Basal and postmethionine load And 26.
plasma homocysteine levels in-patients with chronic liver disease. *J Hepatol Suppl* 1 30:1999.
- Assy N, Kraizer Y, **Baruch Y**, Dabbach B, Spira G. Vascular endothelial growth factor 27.
And respective monoclonal antibodies can modulate liver cell proliferation following partial
Hepatectomy in rats. *Hepatology* 30:61A, 1999.
- Baruch Y**, Barak S, Machtei EE, Oettinger-Barak O, Peled M, Ardekian L, Laufer D. 28.
The effect of liver disease and liver transplantation on alveolar bone height.
Hepatology 30: 665A, 1999.
- Weitzman E, Shenkar L, Shoshany G, Kasinetz L, Gershoni-Baruch R, **Baruch Y**. 29.
Detection of transplanted hepatocytes by semi-quantitative analysis, using PCR and FISH for the
sry region on the Y-Chromosome. *Hepatology* 188A, October 1999.
- Tassopoulos N, Hadziyannis S, Ideo G, Jurewicz R, Young C, Saltzman R, Trepo C, Bonino F. 30.
for the Famciclovir Anti-HBe + Chronic Hepatitis B Study Group.
Famciclovir treatment of Anti-HBe positive chronic hepatitis B results of a randomised, placebo-
controlled study. EASL, Rotterdam, May 2000.
- Oettinger-Barak O, Barak S, Ardekian L, **Baruch Y**, Laufer D, Machtei EE. 31.
Gingival and radiographic changes in Tacrolimus versus Cyclosporine-A treated patients.
J Dent Res (Suppl.) 2000.
- Perets A, Cohen S, Wiesbuch F, Shenkar L, Shoshany G, Neufeld G, **Baruch Y**. 32.
Alginate composites containing vascular growth factors enhance scaffolds angiogenesis as a first
step before hepatocyte transplantation. AASLD, Dallas, November 2001.
- Baruch Y**, Neubauer K, Shenkar L, Ramadori R. Von Willebrand Factor expression and plasma 33.
levels after partial hepatectomy in the rat. EASL Prague, April 2001.
(Selected as a representative work for 2001 by the EASL scientific committee).
- Shani H, Tshiperson V, Shoshany G, Veitzmen E. Neufeld G, **Baruch Y**. 34.
The effect of VEGF on hepatocyte engraftment after intrasplenic cell transplantation in the rat.
EASL, Madrid 2002.
- Tshiperson V., Ilan N, Shoshany G, Goldshmidt O, Vlodaysky V, **Baruch Y**. 35.
The effect of Heparanase on hepatocyte engraftment after intrasplenic cell
transplantation in the rat. EASL, Istanbul, April 2003.
- Farber E, Fisher D, Eliakim R, Beck-Razi N, Angel A, Veitsman E, Chermesh I, 36.
Yassin C, Gaitini D, Libas M, Soboh S, **Baruch Y**. Barium Esophagogram (BE) versus Upper

Endoscopy (EGD) for the screening of esophageal varices (EV) in patients with compensated cirrhosis – a blinded prospective study. AASLD, Boston, October 2003.

Shani H, Tshiperson V, Shoshany G, Veitzmen E. Neufeld G, **Baruch Y.** 37.
The effect of VEGF on hepatocyte engraftment after intrasplenic cell transplantation in the rat. AASLD, Boston, October 2003.

Baruch Y, Boyanjo I, Tshiperson V, et al. Heparanase and hVEGF₁₆₅ increase intravascular survival of transplanted Hepatocytes and EC proliferation in rats after partial hepatectomy, ILTS, Rio-de Janeiro, June 2007. Liver Transplantation 13:5104, 2007 (Abs 147). 38.

Carmel J, Arish A, Ilan N, Shoshany G, Vlodaysky I, **Baruch Y.** Heparanase stimulates hepatocytes and sinusoidal endothelial cell proliferation in the rat early and late after partial hepatectomy. San Francisco, AASLD 2008. 39.

Veitsman E, Edoardo S, Hassoun G, Lorber M, Maor K, Kramskay R, Pollack S, **Baruch Y.** High sustained virological response to peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience. San Francisco, AASLD 2008. 40.

R. Kramskay, A. Tansky, E. Eisenberg, E. Veitsman and **Baruch Y.** 41.
Prevention of Pain and Anxiety Associated with Percutaneous Liver Biopsy: A Randomized Study. EASL Vienna, Austria 2010.

T. Saadi, A. Arish, J. Carmel, Z. Bramnik, O. Nayshool, I. Mironi-Harpaz, D. Seliktar, **Baruch Y.** Hepatocyte cell line function in a biosynthetic hydrogel scaffold for liver tissue engineering. EASL Vienna, Austria 2010. 42.

J. Carmel, A. Arish, N. Ilan, G. Shoshany, I. Vlodaysky and **Baruch Y.** 43.
Heparanase accelerates proliferation of both hepatocytes and sinusoidal endothelial cells after partial hepatectomy despite IL-6 and TNF- α down regulation. EASL Vienna, Austria 2010.

Pianko S, Lurie Y, **Baruch Y**, Leggett B, Hughes B, Shouval D, Crawford D, Bell S, et al; Final results of ACHIEVE-1: albinterferon alfa-2b plus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. APASL Beijing 2010. 44.

M. Woynarowski, A. Nemeth, **Baruch Y**, S. Koletzko, M. Melter, B. Rodeck, C. Strassburg, M. Prots, MP. Manns, and the European AIH-BUS-Study Group. 45.
Budesonide 3 mg tid in the treatment of autoimmune hepatitis (AIH) in adolescents, a subgroup analysis of the European AIH-BUS-Study. EASL Berlin 2011.

Baruch Y. Liver Tissue engineering, International Hepatobiliary, Pancreatic and transplantation surgery (IHPB). Jerusalem, May 2011. 46.

B. Makhoul, E. Weitzman. M. Libes and **Y. Baruch.** Low Incidence of Liver Damage in Non Alcoholic High Risk Patients with Psoriasis Exposed to High Dose Methotrexate. San Francisco, AASLD 2011 . 47.

O. Nayshool, J. Carmel, T. Saadi, A. Arish, Z. Bramnik , I. Mironi-Harpaz, D. Seliktar, **Y. Baruch.** Microcapsules made of biosynthetic hydrogel scaffolds, for intravascular liver tissue regeneration therapy. San Francisco, AASLD 2011. 48.

J. Carmel, O. Nayshool, T. Saadi, A. Arish, Z. Bramnik , U. Kaplan , I. Mironi-Harpaz, 49.

D. Seliktar, **Y. Baruch**. Micro cell-compatible hydrogels, allow for long term hepatocytes engraftment after intravascular transplantation. Washington, AASLD, Hepatology 58:4, 2013 (Abs 337).